5.7 CLIA, Laboratory-Developed Tests & FDA Oversight
Key Takeaways
- CLIA regulates laboratory operations — personnel, quality control, proficiency testing, and validation — and results from a non-CLIA-certified laboratory may not be used for clinical decision-making.
- CLIA governs analytic performance; it does not evaluate whether a test is clinically valid or clinically useful for a given indication.
- Most genetic tests are laboratory-developed tests designed, validated, and performed within a single laboratory rather than FDA-cleared or approved kits.
- Research results must be confirmed in a CLIA-certified laboratory before being used to guide clinical management, which is why a research finding triggers clinical confirmatory testing.
- Direct-to-consumer raw data files are not clinically validated and carry high false-positive rates for individual variants, so they require confirmatory clinical testing before any management decision.
5.7 CLIA, Laboratory-Developed Tests & FDA Oversight
Quick Answer: CLIA certifies laboratory operations — personnel qualifications, quality control, validation, and proficiency testing — and a result used for clinical decision-making must come from a CLIA-certified laboratory. CLIA does not assess clinical validity or utility. Most genetic tests are laboratory-developed tests (LDTs) rather than FDA-cleared kits. Research results and DTC raw data require CLIA-certified confirmation before they drive management.
Subdomain 5C carries 11 scored items on legal and regulatory requirements. Alongside non-discrimination, privacy, documentation, research standards, and patient access, candidates are expected to know the regulatory scaffolding under the reports they interpret — and to recognize the classic vignette in which a result cannot yet be acted on.
CLIA: what it actually regulates
The Clinical Laboratory Improvement Amendments (CLIA) are federal requirements administered by CMS that apply to any laboratory testing human specimens for the purpose of diagnosis, prevention, or treatment. Genetic testing sits in the high-complexity category, which carries the most demanding requirements.
| CLIA requirement | What it means in a genetics laboratory |
|---|---|
| Personnel standards | Defined qualifications for the laboratory director, technical supervisor, and testing personnel; the director signs out reports and holds regulatory responsibility |
| Analytic validation | Before clinical use, the laboratory must establish accuracy, precision, analytic sensitivity and specificity, reportable range, and reference intervals for each assay |
| Quality control and quality assurance | Ongoing controls, documented corrective action, and periodic review |
| Proficiency testing | Periodic blinded external challenge samples for regulated analytes, with graded performance |
| Specimen and record retention | Defined retention periods for specimens, reports, and quality records |
| Inspection | Biennial survey by CMS or a CMS-approved accrediting organization |
CAP accreditation (College of American Pathologists) is the most common deemed-status route: a laboratory accredited by CAP satisfies CLIA through CAP's more detailed molecular checklists and proficiency programs. ISO 15189 accreditation appears in some settings, particularly internationally.
The distinction the exam actually tests
CLIA answers "can this laboratory reliably detect what it says it detects?" — analytic validity. It does not answer:
- Clinical validity — does the variant this laboratory reliably detects actually predict the disease?
- Clinical utility — does knowing the result improve outcomes?
So a CLIA-certified laboratory can produce a technically flawless report on a gene-disease relationship with limited or disputed evidence. Assessing that evidence is the counselor's job, using resources such as ClinGen gene-disease validity classifications — not something CLIA certification settles.
Laboratory-developed tests and FDA oversight
Most clinical genetic tests are laboratory-developed tests: assays designed, validated, and performed within a single laboratory rather than manufactured and distributed as kits.
| Category | Regulatory route | Genetics examples |
|---|---|---|
| LDT | Historically overseen through CLIA rather than premarket FDA review | Most hereditary cancer panels, exome and genome sequencing, most carrier screens |
| FDA-cleared or approved in vitro diagnostic | 510(k) clearance or premarket approval | Selected companion diagnostics and a limited number of consumer genetic health risk reports |
| Companion diagnostic | FDA-approved, tied to a specific therapeutic | Tests required to determine eligibility for a targeted therapy |
FDA has asserted authority over LDTs at various points and the scope of that oversight has been repeatedly contested and litigated. The exam-safe framing is that LDT oversight is a live and shifting regulatory question, that the historical default has been CLIA-based oversight without premarket FDA review, and that a specific test's regulatory status should be verified rather than assumed. Do not memorize a rule that may have changed; know the two frameworks and the difference between them.
The confirmation rules that generate exam items
Research results
A finding generated in a research laboratory that is not CLIA-certified may not be used to guide clinical management. When a research study identifies a variant a participant wishes to act on, the pathway is confirmatory testing in a CLIA-certified clinical laboratory, with clinical consent and counseling. This is why research consent documents specify whether results will be returned at all, and why "the study told me I have a BRCA mutation" is the start of a clinical workup rather than a diagnosis.
Direct-to-consumer results and raw data
| Product type | Clinical standing |
|---|---|
| DTC health risk reports on a limited variant set | Report only the specific variants tested; a "negative" excludes almost nothing, since most pathogenic variants in a gene are not on the array |
| DTC raw data files | Not clinically validated; third-party interpretation of these files produces high false-positive rates for individual variants |
| DTC-initiated tests performed in a CLIA laboratory | Analytic quality may be adequate, but interpretation and counseling context still require clinical review |
The counseling rule is unchanged in either direction: a DTC "positive" requires confirmation in a clinical laboratory before any management change, and a DTC "negative" does not exclude hereditary risk in someone whose personal or family history meets testing criteria. Both errors — acting on an unconfirmed DTC positive and dismissing a strong pedigree because of a DTC negative — appear as distractors.
Reflex confirmation within clinical testing
Even inside CLIA-certified clinical laboratories, high-throughput sequencing findings are commonly confirmed by an orthogonal method or by high-quality read review before reporting, and results driving irreversible decisions — prenatal diagnosis, risk-reducing surgery, cascade testing — warrant confirmation of the specific variant. A counselor asking "was this confirmed, and by what method?" is asking a Domain 5C question, not being difficult.
The laboratory director's role and the counselor's boundary
Under CLIA, the laboratory director carries regulatory responsibility for test validation, quality systems, and report sign-out. A genetic counselor — unless separately qualified and appointed to that role — interprets the report in the counseling context but does not override, re-issue, or informally reclassify a signed laboratory result. Disagreement with a classification is routed through the laboratory's variant review process, with the supporting clinical or segregation evidence supplied. This is the regulatory basis for the scope-of-practice teaching elsewhere in Domain 5D.
Common traps
- Treating CLIA certification as evidence that a test is clinically valid or useful.
- Acting on a research result without CLIA-certified confirmation.
- Treating a DTC raw data variant call as a clinical result, or a DTC negative as excluding hereditary risk.
- Assuming every genetic test is FDA-approved; most are LDTs.
- Reclassifying a laboratory's variant call informally instead of submitting evidence through the laboratory's process.
- Confusing CAP accreditation with a separate legal requirement rather than a deemed-status route to CLIA compliance.
A patient enrolled in a research study is told that sequencing performed in the investigators’ research laboratory identified a pathogenic BRCA1 variant. She asks to schedule risk-reducing surgery. What is the appropriate next step?
What does CLIA certification of a laboratory establish, and what does it not establish?
A 45-year-old woman with a mother and sister diagnosed with breast cancer before age 50 reports that a direct-to-consumer test showed she does not carry the BRCA variants tested. She asks whether she still needs clinical genetic testing. What is the most accurate counseling?
Which statement best describes the regulatory status of most clinical genetic tests currently in use?